BioStock Studio: Scandion Oncology brings in New CEO

Scandion Oncology’s top candidate, SCO-101, is currently in a phase II clinical trial with metastatic colorectal cancer patients. As the study progresses, the company is beginning a new phase in its development program. In light of this, the company has appointed Bo Rode Hansen as CEO, while former CEO Nils Brünner takes the role as CSO, to strengthen its executive leadership. Both Rode Hansen and Brünner came to the BioStock studio to discuss the change.Watch the full interview with Scandion Oncology’s CEO Bo Rode Hansen and CSO Nils Brünner below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev